for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

aTyr Pharma Inc

LIFE.O

Latest Trade

3.90USD

Change

-0.03(-0.76%)

Volume

17,419

Today's Range

3.82

 - 

3.95

52 Week Range

2.76

 - 

12.33

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.93
Open
3.86
Volume
17,419
3M AVG Volume
2.42
Today's High
3.95
Today's Low
3.82
52 Week High
12.33
52 Week Low
2.76
Shares Out (MIL)
3.89
Market Cap (MIL)
16.14
Forward P/E
-1.74
Dividend (Yield %)
--

Latest Developments

More

Atyr Posts Qtrly Loss Per Share Of $1.80

Atyr Pharma Announces Reverse Stock Split To Regain Nasdaq Compliance

Atyr Pharma Files For Mixed Shelf Of Up To $20 Million – SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About aTyr Pharma Inc

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Industry

Biotechnology & Drugs

Contact Info

3545 John Hopkins Ct Ste 250

+1.858.7318389

http://www.atyrpharma.com/

Executive Leadership

John K. Clarke

Independent Chairman of the Board

Sanjay S. Shukla

President, Chief Executive Officer, Chief Medical Officer

Jill M. Broadfoot

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Grove Matsuoka

Senior Vice President, Product Programs and Planning

Ashraf Amanullah

Vice President, Biologics Development and Manufacturing

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
EPS (USD)

2016

-34.160

2017

-26.180

2018

-16.100

2019(E)

-2.379
Price To Earnings (TTM)
--
Price To Sales (TTM)
171.75
Price To Book (MRQ)
0.48
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
41.08
LT Debt To Equity (MRQ)
15.22
Return on Investment (TTM)
-53.70
Return on Equity (TTM)
-43.43

Latest News

BRIEF-Atyr Pharma Inc Posts Qtrly Loss Of $0.36 Per Share

* ATYR PHARMA ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS, PROGRAM PRIORITIZATION AND CORPORATE RESTRUCTURING

BRIEF-Atyr Pharma Q4 Loss Per Share $0.39

* ATYR PHARMA ANNOUNCES FOURTH QUARTER AND YEAR-END 2017 OPERATING RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Atyr Pharma Says On Dec 22, Co Entered Into Amendment To Loan And Security Agreement Dated As Of Nov 18, 2016

* ATYR PHARMA SAYS ON DEC 22, CO ENTERED INTO AMENDMENT TO LOAN AND SECURITY AGREEMENT DATED AS OF NOV 18, 2016 - SEC FILING

BRIEF-aTyr Pharma reports qtrly ‍net loss per share, basic and diluted $0.43​

* aTyr Pharma announces third quarter 2017 operating results and provides corporate update

BRIEF-Atyr Pharma files for resale of up to 23.6 mln shares of common stock by selling stockholders - SEC Filing

* Atyr Pharma Inc files for resale of up to 23.6 million shares of common stock by selling stockholders - SEC Filing Source text: [http://bit.ly/2h4V7rA] Further company coverage:

BRIEF-‍Viking Global Investors reports 9.5 pct passive stake in aTyr Pharma​

* Viking Global Investors Lp reports 9.5 percent passive stake in aTyr Pharma Inc as on August 31, 2017 - SEC filing Source text : (http://bit.ly/2vP2d66) Further company coverage:

BRIEF-Atyr Pharma qtrly ‍net loss per share $0.51​

* Atyr Pharma announces second quarter 2017 operating results and provides an update on innovative immunology pipeline

BRIEF-ATyr pharma enters into first amendment to loan and security agreement

* ATyr Pharma says on june 30, entered into first amendment to loan and security agreement with silicon valley bank and solar capital ltd - SEC filing

BRIEF-aTyr Pharma announces qtrly net loss per share, basic and diluted $0.56

* aTyr Pharma Inc - Qtrly net loss per share, basic and diluted $0.56

BRIEF-Atyr Pharma announces promising top-line results from Resolaris

* Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy

BRIEF-aTyr Pharma appoints of Timothy P. Coughlin to its board

* aTyr Pharma announces appointment of TIMOTHY P. COUGHLIN to its board of directors Source text for Eikon: Further company coverage:

BRIEF-aTyr Pharma qtrly net loss per share attributable to common stockholders $0.53

* Atyr pharma -continues to expect that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into q3 of 2018

BRIEF-Atyr Pharma reports issuance of U.S. patent that extends patent protection of physiocrines

* Atyr Pharma announces issuance of U.S. patent that extends patent protection of physiocrines derived from 20 out of 20 human TRNA synthetases Source text for Eikon: Further company coverage:

BRIEF-Atyr Pharma receives EMA orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris

* Atyr Pharma receives ema orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris™ Source text for Eikon: Further company coverage:

BRIEF-Atyr Pharma receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris

* Atyr Pharma Receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris™ Source text for Eikon: Further company coverage:

BRIEF-Ecor1 Capital reports 8.3 pct passive stake in Atyr Pharma

* Ecor1 Capital LLC reports 8.3 percent passive stake in Atyr Pharma Inc as of Jan 18 - SEC filing Source text: (http://bit.ly/2kkPDsu) Further company coverage:

BRIEF-FDA grants fast track designation for aTyr's Resolaris

* Fda grants fast track designation for aTyr's Resolaris to treat limb girdle muscular dystrophy 2b and removes partial clinical hold for Resolaris

BRIEF-Atyr Pharma enters into $20 million credit facility

* Intends to use additional capital to pay off existing indebtedness

BRIEF-Atyr Pharma reports Q3 loss per share of $0.58

* Qtrly net loss per share attributable to common stockholders $0.58

BRIEF-Atyr Pharma receives FDA fast track designation for Resolaris to treat FSHD

* Atyr Pharma receives FDA fast track designation for Resolaris to treat facioscapulohumeral muscular dystrophy (FSHD)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up